tetano
Editor, Senior Moderator
Poult Sci
. 2024 Jan 26;103(4):103496.
doi: 10.1016/j.psj.2024.103496. Online ahead of print. Mucosal immune responses and protective efficacy elicited by oral administration AMP-ZnONPs-adjuvanted inactivated H9N2 virus in chickens
Xiaopan Liu[SUP] 1 [/SUP], Hailong Hong[SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Junjie Huang[SUP] 1 [/SUP], Jiawen Li[SUP] 1 [/SUP], Ya Tao[SUP] 1 [/SUP], Mingjiang Liu[SUP] 2 [/SUP], Huan Pang[SUP] 3 [/SUP], Jingui Li[SUP] 2 [/SUP], Ruonan Bo[SUP] 4 [/SUP]
Affiliations
The avian influenza virus is infected through the mucosal route, thus mucosal barrier defense is very important. While the inactivated H9N2 vaccine cannot achieve sufficient mucosal immunity, adjuvants are needed to induce mucosal and systemic immunity to prevent poultry from H9N2 influenza virus infection. Our previous study found that polysaccharide from Atractylodes macrocephala Koidz binding with zinc oxide nanoparticles (AMP-ZnONPs) had immune-enhancing effects in vitro. This study aimed to evaluate the mucosal immune responses of oral whole-inactivated H9N2 virus (WIV)+AMP-ZnONPs and its impact on the animal challenge protection, and the corresponding changes of pulmonary metabolomics after the second immunization. The results showed that compared to the WIV, the combined treatment of WIV and AMP-ZnONPs significantly enhanced the HI titer, IgG and specific sIgA levels, the number of goblet cells and intestinal epithelial lymphocytes (iIELs) as well as the expression of J-chain, polymeric immunoglobulin receptor (pIgR), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β). In viral attack experiments, WIV combing with AMP-ZnONPs effectively reduced lung damage and viral titers in throat swabs. Interestingly, significant changes of both the IgA intestinal immune network and PPAR pathway could also be found in the WIV+AMP-ZnONPs group compared to the non-infected group. Taken together, these findings suggest that AMP-ZnONPs can serve as a potential mucosal vaccine adjuvant, thereby avoiding adverse stress and corresponding costs caused by vaccine injection.
Keywords: HI titer; metabolism; oral mucosal immunoadjuvant; sIgA; virus attack protection.
. 2024 Jan 26;103(4):103496.
doi: 10.1016/j.psj.2024.103496. Online ahead of print. Mucosal immune responses and protective efficacy elicited by oral administration AMP-ZnONPs-adjuvanted inactivated H9N2 virus in chickens
Xiaopan Liu[SUP] 1 [/SUP], Hailong Hong[SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Junjie Huang[SUP] 1 [/SUP], Jiawen Li[SUP] 1 [/SUP], Ya Tao[SUP] 1 [/SUP], Mingjiang Liu[SUP] 2 [/SUP], Huan Pang[SUP] 3 [/SUP], Jingui Li[SUP] 2 [/SUP], Ruonan Bo[SUP] 4 [/SUP]
Affiliations
- PMID: 38330890
- DOI: 10.1016/j.psj.2024.103496
The avian influenza virus is infected through the mucosal route, thus mucosal barrier defense is very important. While the inactivated H9N2 vaccine cannot achieve sufficient mucosal immunity, adjuvants are needed to induce mucosal and systemic immunity to prevent poultry from H9N2 influenza virus infection. Our previous study found that polysaccharide from Atractylodes macrocephala Koidz binding with zinc oxide nanoparticles (AMP-ZnONPs) had immune-enhancing effects in vitro. This study aimed to evaluate the mucosal immune responses of oral whole-inactivated H9N2 virus (WIV)+AMP-ZnONPs and its impact on the animal challenge protection, and the corresponding changes of pulmonary metabolomics after the second immunization. The results showed that compared to the WIV, the combined treatment of WIV and AMP-ZnONPs significantly enhanced the HI titer, IgG and specific sIgA levels, the number of goblet cells and intestinal epithelial lymphocytes (iIELs) as well as the expression of J-chain, polymeric immunoglobulin receptor (pIgR), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β). In viral attack experiments, WIV combing with AMP-ZnONPs effectively reduced lung damage and viral titers in throat swabs. Interestingly, significant changes of both the IgA intestinal immune network and PPAR pathway could also be found in the WIV+AMP-ZnONPs group compared to the non-infected group. Taken together, these findings suggest that AMP-ZnONPs can serve as a potential mucosal vaccine adjuvant, thereby avoiding adverse stress and corresponding costs caused by vaccine injection.
Keywords: HI titer; metabolism; oral mucosal immunoadjuvant; sIgA; virus attack protection.